Login to Your Account



Another Drug in the 'Lexicon'

Salix Liver-Failure Win Puts Spotlight on Xifaxan in IBS

By Randy Osborne


Monday, April 5, 2010
Salix Pharmaceuticals Inc.'s path forward should become clear shortly with the approved antibiotic Xifaxan in its third potential, and much-coveted, indication: irritable bowel syndrome. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription